New drug DFV890 aims to ease knee arthritis pain
NCT ID NCT04886258
First seen Jan 29, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tested an experimental drug called DFV890 in 115 people with painful knee osteoarthritis. The goal was to see if it reduces pain and improves knee function compared to a placebo. Participants were aged 50 to 80 and had moderate to severe pain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYMPTOMATIC KNEE OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARENSIA Explor Med Res Clinic
Phoenix, Arizona, 85015, United States
-
Conquest Research
Winter Park, Florida, 32789, United States
-
Ctr for Adv Research and Education
Gainesville, Georgia, 30501, United States
-
IRIS Research and Development
Plantation, Florida, 33324, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Novartis Investigative Site
CABA, Buenos Aires, C1181ACH, Argentina
-
Novartis Investigative Site
San Miguel, Tucumán Province, T4000CBC, Argentina
-
Novartis Investigative Site
San Miguel de Tucumán, 4000, Argentina
-
Novartis Investigative Site
Brno, Czech Republic, 66250, Czechia
-
Novartis Investigative Site
Nový Jičín, 741 01, Czechia
-
Novartis Investigative Site
Prague, 150 06, Czechia
-
Novartis Investigative Site
Uherské Hradiště, 686 01, Czechia
-
Novartis Investigative Site
Bad Doberan, 18209, Germany
-
Novartis Investigative Site
Berlin, 10787, Germany
-
Novartis Investigative Site
Hamburg, 22143, Germany
-
Novartis Investigative Site
Hamburg, 22415, Germany
-
Novartis Investigative Site
Leipzig, 04107, Germany
-
Novartis Investigative Site
Kecskemét, Bács-Kiskun county, 6044, Hungary
-
Novartis Investigative Site
Budapest, 1027, Hungary
-
Novartis Investigative Site
Miskolc, 3526, Hungary
-
Novartis Investigative Site
Veszprém, 8200, Hungary
-
Novartis Investigative Site
Cluj-Napoca, Cluj, 400006, Romania
-
Novartis Investigative Site
Bucharest, 011658, Romania
-
Novartis Investigative Site
Nové Mesto nad Váhom, 915 01, Slovakia
-
Novartis Investigative Site
Piešťany, 921 01, Slovakia
-
Novartis Investigative Site
Sabadell, Barcelona, 08208, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08003, Spain
-
Novartis Investigative Site
A Coruña, 15006, Spain
-
Novartis Investigative Site
Seville, 41010, Spain
-
Skylight Health Res Inc Color Spr
Colorado Springs, Colorado, 80917, United States
-
TriWest Reserach Associates
El Cajon, California, 92020, United States
Conditions
Explore the condition pages connected to this study.